Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab

Expert Opinion on Drug Safety
Mario CazzolaPaola Rogliani

Abstract

Reslizumab, a humanized mAb against IL-5, reduces the number of eosinophils in the blood and lungs. Based on efficacy and safety data from pivotal RCTs, reslizumab had been approved for use as an add-on maintenance treatment of severe asthma with an eosinophilic phenotype in adults who have a history of exacerbations despite receiving their current asthma medicines. Areas covered: Current literature on reslizumab has been reviewed with a specific focus on its safety profile in the treatment of severe asthma. Expert opinion: Large pivotal and supportive trials reinforce the view that reslizumab is well tolerated, with an acceptable safety profile in patients exposed for longer than 2 years. However, no or few data concerning safety in special populations such as smokers, those with immune- and cellular senescence, patients with comorbidities and those receiving multi-drug treatments are available as yet. Furthermore, we need to fully elucidate some fundamental issues such as the risk of anaphylaxis and the long-term risk-benefit ratio of the impact of depletion of eosinophils and the potential risk of malignancies induced by a treatment with this anti-IL-5 agent.

References

Jan 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·A SherA W Cheever
Oct 11, 1990·The New England Journal of Medicine·J BousquetP Godard
Aug 1, 1995·American Journal of Respiratory and Critical Care Medicine·P J MauserR W Chapman
Sep 1, 1995·American Journal of Respiratory Cell and Molecular Biology·T T KungR W Chapman
Jan 28, 1998·American Journal of Respiratory and Critical Care Medicine·H Z ShiZ F Xie
Mar 22, 2003·American Journal of Respiratory and Critical Care Medicine·Johan C KipsRomain A Pauwels
Jul 23, 2005·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Chien-Da HuangHan-Pin Kuo
Jul 27, 2006·Allergy·W J Pichler
Nov 13, 2007·Immunology and Allergy Clinics of North America·June Y Zhang, Sally E Wenzel
Apr 16, 2008·The Journal of Allergy and Clinical Immunology·Miguel L SteinMarc E Rothenberg
Nov 8, 2008·Expert Opinion on Biological Therapy·Jean BousquetMarc Humbert
Nov 12, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Fanny LegrandMonique Capron
Aug 20, 2011·American Journal of Respiratory and Critical Care Medicine·Mario CastroUNKNOWN Res-5-0010 Study Group
Dec 17, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Masashi IkutaniKiyoshi Takatsu
Jun 19, 2012·Cancer Immunology, Immunotherapy : CII·Solène GataultMonique Capron
Oct 11, 2012·Immunological Reviews·Sophie E BroughtonMichael W Parker
Jan 8, 2013·Nature Reviews. Immunology·Jennifer A WalkerAndrew N J McKenzie
Jun 8, 2013·Allergy·G J GleichP F Weller
Oct 15, 2014·The Journal of Allergy and Clinical Immunology·Katsuyuki TakedaErwin W Gelfand
Dec 24, 2014·The Journal of Allergy and Clinical Immunology·Dorothy S Cheung, Mitchell H Grayson
Sep 8, 2015·The Journal of Allergy and Clinical Immunology. in Practice·Jay J JinCatherine R Weiler
May 27, 2016·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Hai LongQianjin Lu
Jul 21, 2016·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Jinfeng LiJiaxing Sun
Oct 27, 2016·Current Opinion in Allergy and Clinical Immunology·Andrea MatucciAlessandra Vultaggio
Oct 26, 2016·Microbiology Spectrum·Ting Wen, Marc E Rothenberg
Dec 30, 2016·Allergy·E Jensen-JarolimS N Karagiannis
May 1, 2017·The Journal of Allergy and Clinical Immunology·Patrick W SullivanMichael Schatz
May 31, 2017·Clinical and Experimental Dermatology·S PathaniaS Handa
Nov 11, 2017·The Journal of Allergy and Clinical Immunology. in Practice·Kevin MurphyMario Castro
Nov 13, 2017·Analytical Biochemistry·Noriko IwamotoTakashi Shimada
Dec 23, 2017·Expert Opinion on Drug Metabolism & Toxicology·Maria Gabriella MateraMario Cazzola
Jan 9, 2018·Oncoimmunology·Gilda VarricchiGiovanna Schiavoni

❮ Previous
Next ❯

Citations

Jun 26, 2018·Expert Opinion on Biological Therapy·Shiven S PatelJuan Carlos Cardet
Aug 16, 2019·Expert Review of Respiratory Medicine·Federica PorcaroGiovanni Battista Pajno
Jun 15, 2021·Clinical and Translational Allergy·Lisha LiBin Zhao
May 29, 2019·Respiratory Medicine·Maria Gabriella MateraMario Cazzola

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

Expert Opinion on Biological Therapy
Juan C Cardet, Elliot Israel
Expert Opinion on Drug Metabolism & Toxicology
Maria Gabriella MateraMario Cazzola
Therapeutics and Clinical Risk Management
Girolamo PelaiaRosario Maselli
© 2022 Meta ULC. All rights reserved